Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1990 Jan;28(1):11–15. doi: 10.1128/jcm.28.1.11-15.1990

Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines.

D I Bernstein 1, R L Ashley 1, L R Stanberry 1, M G Myers 1
PMCID: PMC269528  PMID: 2153698

Abstract

The evaluation of herpes simplex virus (HSV) vaccine efficacy will require methods to detect asymptomatic acquisition of HSV infection and to assess the risk of recurrences in these patients. HSV-infected vaccinees should develop antibodies to HSV polypeptides not included in subunit vaccines. Sera from 57 HSV glycoprotein-vaccinated guinea pigs that had asymptomatic initial infections after genital HSV type 2 challenge were collected after vaccination but before HSV challenge and again 30 days after HSV challenge to determine the antibody response to HSV polypeptides. Antibodies to nonvaccine HSV polypeptides were detected in sera collected after viral challenge from 32 (56%) of these 57 animals. Twenty-six (81%) of the 32 animals with detectable antibody developed recurrent disease; however, recurrences also developed in 11 (44%) of the remaining 25 that did not show detectable antibody to nonvaccine HSV polypeptides. The magnitude of vaginal viral shedding during the initial disease period following challenge was significantly lower in animals that did not develop antibody to nonvaccine polypeptides compared with those that did develop antibody (area under the viral shedding curve, 5.2 +/- 3.2 versus 18.1 +/- 5.8; P less than 0.0001) . These data suggest that detection of antibody to nonvaccine HSV polypeptides will identify the majority (70%) of initially asymptomatic vaccinees that develop recurrent disease but that latency can be established even with markedly reduced levels of viral replication that did not induce a detectable antibody response.

Full text

PDF
11

Images in this article

13Image
on p.13
13Image
on p.13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashley R. L., Militoni J., Lee F., Nahmias A., Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988 Apr;26(4):662–667. doi: 10.1128/jcm.26.4.662-667.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ashley R., Benedetti J., Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol. 1985 Oct;17(2):153–166. doi: 10.1002/jmv.1890170208. [DOI] [PubMed] [Google Scholar]
  3. Ashley R., Mertz G. J., Corey L. Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol. 1987 Feb;61(2):264–268. doi: 10.1128/jvi.61.2.264-268.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berman P. W., Gregory T., Crase D., Lasky L. A. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science. 1985 Mar 22;227(4693):1490–1492. doi: 10.1126/science.2983428. [DOI] [PubMed] [Google Scholar]
  5. Berman P. W., Vogt P. E., Gregory T., Lasky L. A., Kern E. R. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis. 1988 May;157(5):897–902. doi: 10.1093/infdis/157.5.897. [DOI] [PubMed] [Google Scholar]
  6. Bernstein D. I., Lovett M. A., Bryson Y. J. Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med. 1984 Dec;77(6):1055–1060. doi: 10.1016/0002-9343(84)90188-8. [DOI] [PubMed] [Google Scholar]
  7. Bernstein D. I., Stanberry L. R., Harrison C. J., Kappes J. C., Myers M. G. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J Gen Virol. 1986 Aug;67(Pt 8):1601–1612. doi: 10.1099/0022-1317-67-8-1601. [DOI] [PubMed] [Google Scholar]
  8. Bernstein D. I., Stanberry L. R., Harrison C. J., Shukla R., Kappes J. C., Myers M. G. Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence. J Infect Dis. 1987 Sep;156(3):423–429. doi: 10.1093/infdis/156.3.423. [DOI] [PubMed] [Google Scholar]
  9. Bernstein D. I., Stanberry L. R., Kappes J. C., Burke R. L., Myers M. G. Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines. J Infect Dis. 1988 Jun;157(6):1178–1186. doi: 10.1093/infdis/157.6.1178. [DOI] [PubMed] [Google Scholar]
  10. Braun D. K., Roizman B., Pereira L. Characterization of post-translational products of herpes simplex virus gene 35 proteins binding to the surfaces of full capsids but not empty capsids. J Virol. 1984 Jan;49(1):142–153. doi: 10.1128/jvi.49.1.142-153.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
  12. Dix R. D., Mills J. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. J Med Virol. 1985 Sep;17(1):9–18. doi: 10.1002/jmv.1890170103. [DOI] [PubMed] [Google Scholar]
  13. Langenberg A., Benedetti J., Jenkins J., Ashley R., Winter C., Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med. 1989 Jun 1;110(11):882–887. doi: 10.7326/0003-4819-110-11-882. [DOI] [PubMed] [Google Scholar]
  14. Long D., Madara T. J., Ponce de Leon M., Cohen G. H., Montgomery P. C., Eisenberg R. J. Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect Immun. 1984 Feb;43(2):761–764. doi: 10.1128/iai.43.2.761-764.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mertz G. J., Coombs R. W., Ashley R., Jourden J., Remington M., Winter C., Fahnlander A., Guinan M., Ducey H., Corey L. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis. 1988 Jun;157(6):1169–1177. doi: 10.1093/infdis/157.6.1169. [DOI] [PubMed] [Google Scholar]
  16. Mertz G. J., Peterman G., Ashley R., Jourden J. L., Salter D., Morrison L., McLean A., Corey L. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis. 1984 Aug;150(2):242–249. doi: 10.1093/infdis/150.2.242. [DOI] [PubMed] [Google Scholar]
  17. Nahmias A. J., Roizman B. Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med. 1973 Oct 11;289(15):781–789. doi: 10.1056/NEJM197310112891505. [DOI] [PubMed] [Google Scholar]
  18. Prober C. G., Hensleigh P. A., Boucher F. D., Yasukawa L. L., Au D. S., Arvin A. M. Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med. 1988 Apr 7;318(14):887–891. doi: 10.1056/NEJM198804073181404. [DOI] [PubMed] [Google Scholar]
  19. Rooney J. F., Felser J. M., Ostrove J. M., Straus S. E. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med. 1986 Jun 12;314(24):1561–1564. doi: 10.1056/NEJM198606123142407. [DOI] [PubMed] [Google Scholar]
  20. Sanchez-Pescador L., Burke R. L., Ott G., Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol. 1988 Sep 1;141(5):1720–1727. [PubMed] [Google Scholar]
  21. Stanberry L. R., Bernstein D. I., Burke R. L., Pachl C., Myers M. G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis. 1987 May;155(5):914–920. doi: 10.1093/infdis/155.5.914. [DOI] [PubMed] [Google Scholar]
  22. Stanberry L. R., Burke R., Myers M. G. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J Infect Dis. 1988 Jan;157(1):156–163. doi: 10.1093/infdis/157.1.156. [DOI] [PubMed] [Google Scholar]
  23. Stanberry L. R., Kern E. R., Richards J. T., Abbott T. M., Overall J. C., Jr Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis. 1982 Sep;146(3):397–404. doi: 10.1093/infdis/146.3.397. [DOI] [PubMed] [Google Scholar]
  24. Stanberry L. R., Kern E. R., Richards J. T., Overall J. C., Jr Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology. 1985;24(4):226–231. doi: 10.1159/000149647. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES